PTH在治疗骨质疏松症及其作用机制的研究进展

摘要

随着我国逐渐步入老龄化社会,骨质疏松症及其并发症将给社会带来巨大的负担.甲状旁腺激素(Parathyroid hormone,PTH)是由84个氨基酸组成的直链肽,与传统的抗骨质疏松药物不同,其可以调整骨转换状态,重塑骨小梁,使得骨量增加,降低骨质疏松骨折风险,因此在众多抗骨质疏松药物中备受关注.随着对PTH治疗骨质疏松症的研究不断深入,甲状旁腺相关肽PTHrP、甲状旁腺1型受体PTHlR、胰岛素样生长因子1 (IGF-1)等先后被发现在PTH激活PTHlR抗骨质疏松中发挥作用,本文将有关研究进展做一综述.%As the population ages in our country,osteoporosis disease and its complications will bring huge burden to the society.Parathyroid hormone (PTH),which consists of 84 amino acids linear peptide,unlike traditional anti osteoporosis drug,can adjust the state of bone turnover,reshape the trabecular bone,which leads to increased bone mass and reduces the risk of osteoporosis fracture.Therefore it has attracted much attention in many anti osteoporosis drug.As the further study of PTH treatment of osteoporosis,parathyroid hormone-related peptide (PTHrP),parathyroid hormone type 1 receptor (PTH1R),insulin-like growth factor 1 (IGF-1) have been discovered in the PTH activation PTHI R anti osteoporosis function.This review is mean to illustrate the research progress briefly.